Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

After the Duchess of Sussex announced her American Riviera Orchard rebrand, she once again is facing accusations of ...

NEW YORK, NY / ACCESS Newswire / February 15, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...

The Food and Drug Administration (FDA) announced that Penmenvy will be allowed for use in individuals aged 10-to-25 years old following two successful Phase III trials. GSK said safety data from ...

Meghan Markle included a sentimental nod to her husband Prince Harry in the logo for her lifestyle brand As Ever, formerly ...

DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

To submit your design, email it to [email protected] or mail it to the Kentucky Department of Veterans Affairs, ATTN: ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.